Search Results

You are looking at 101 - 110 of 444 items for :

  • Refine by Access: All x
Clear All
Full access

Margaret Tempero

hand, a course of ipilimumab for treating metastatic malignant melanoma costs about $120,000. If I had metastatic malignant melanoma and this drug worked for me, I would live longer. But I might have complications from the drug, and I would still

Full access

utilizing language for non-professional audiences. The NCCN Guidelines for Patients can be accessed at NCCN.com . Highlights of the NCCN 17th Annual Conference Include Presentations on Lung Cancer Screening, Melanoma, and Non-Hodgkin’s Lymphomas

Full access

William Blum

is ipilumumab, an mAb-targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), previously shown to improve survival in metastatic melanoma. 5 Combining ipilumumab with nivolumab (targeting programmed death [PD]-1) improved the response rate

Full access

Maria Cassandre Medor, Sylia Mohand-Said, Andrea Ibrahim, Laura Baker, Audrey Litvak, Moein Momtazi, and Carolyn Nessim

Background: Lymphedema is a form of soft tissue swelling from interstitial accumulation of fluid due to disruption of the lymphatic system. In melanoma patients, the incidence of lymphedema ranges from 5-10% in upper extremity and 28-40% in lower

Full access

Yuqi Zhang, Marcelo Cerullo, Andrew Esposito, and Vishnukamal Golla

of price disclosure of surgical procedures for five cancers (Breast, Lung, Melanoma, Colon, and Prostate) among hospitals ranked by the American College of Surgeon’s Commission on Cancer (CoC). Methods : We identified non-federal, adult, and non

Full access

Tina J. Hieken, Mariana B. Sadurní, Enrica Quattrocchi, Ajdin Kobic, Sindhuja Sominidi-Damodaran, Lisette Meerstein, Jvalini T. Dwarkasing, Alina G. Bridges, and Alexander Meves

Background : The value of sentinel lymph node (SLN) surgery for patients with clinically node-negative T1b through T3 cutaneous melanomas is well-established. However, further precision in selecting patients for SLN surgery would be desirable as

Full access

Tanner M. Johanns, George Ansstas, and Sonika Dahiya

Use of small molecule inhibitors specific to activating BRAF V600 mutations first demonstrated efficacy in metastatic melanoma. 1 Recently, similar results were observed in patients with BRAF -mutated non–small cell lung cancer, leading to FDA

Full access

Karisa C. Schreck, Andrew Guajardo, Doris D.M. Lin, Charles G. Eberhart, and Stuart A. Grossman

leads to cell proliferation and survival. BRAF V600E is the most common mutation, although there are others that occur less frequently (V600K/D/R). BRAF-specific inhibitors have been developed and are effective in melanoma, with approximately 50% of

Full access

Jonathan S. Zager, Jane L. Messina, L. Frank Glass, and Vernon K. Sondak

.org ). Evaluation of the Primary Tumor In many ways, MCC is analogous to thick melanoma: most lesions are thick and deeply invasive, regional nodal metastases are commonly identified, and subclinical distant dissemination is present in many patients at diagnosis

Full access

Rona Yaeger and Leonard Saltz

(formerly known as PLX-4032) has achieved high response rates and increased overall survival in patients with V600E BRAF–mutated melanoma. 7 The experience in colorectal tumors with V600E BRAF mutations has revealed only minimal activity for this agent